does AOD-9604 work for weight loss?

AOD-9604 is unusual because the human trial record exists. the uncomfortable part is what that record says.

verdict: pharmacology real, weight-loss claim failed (human data present / efficacy weak)

quick answer

AOD-9604 was developed for obesity and reached human trials. the pharmacology was interesting and safety looked relatively clean, but the obesity program did not show clinically meaningful weight loss.

the evidence

the compound was studied seriously. (supported)

AOD-9604 is not just an internet invention. it went through a real obesity-development arc.

the core weight-loss claim did not survive. (contradicted)

the issue is not that no one looked. the issue is that the program looked and the weight-loss effect was not enough.

GRAS language is commonly misread. (risk)

Generally Recognized As Safe status is not FDA approval as a drug and does not validate weight-loss marketing.

bottom line

one of the rare peptide claims where the human data is not absent; it is negative for the marketed outcome.

scores

• human trials: 64 — actual obesity program existed
• mechanism: 48 — lipolytic fragment idea is real
• regulatory clarity: 38 — GRAS is not drug approval
• marketing gap: 78 — weight-loss ads ignore failed effect size

keep reading

• open AOD-9604 entry — full failed-trial record
• weight-loss category — GLP-1s vs weaker claims
• GLP-1 decade — why the category moved on

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.